Inhibition of arenavirus by A3, a pyrimidine biosynthesis inhibitor

Journal of Virology

Volumn 88, Issue 2, 2014, Pages 878-889

  Ortiz Riaño, Emilio ^a   Ngo, Nhi ^b   Devito, Stefanie ^a   Eggink, Dirk ^c   Munger, Joshua ^a   Shaw, Megan L ^c   De la Torre, Juan Carlos ^b   Martínez Sobrido, Luis ^a  

^a UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^b SCRIPPS RESEARCH INSTITUTE   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

A 3; ANTIVIRUS AGENT; RIBAVIRIN; UNCLASSIFIED DRUG; VIRUS RNA;

ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENTIATION; HAPLORHINI; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; JUNIN VIRUS; LYMPHOCYTIC CHORIOMENINGITIS VIRUS; NONHUMAN; PRIORITY JOURNAL; RNA REPLICATION; VIRUS INHIBITION; VIRUS REPLICATION;

ANIMALS; ANTIVIRAL AGENTS; ARENAVIRIDAE INFECTIONS; ARENAVIRUS; CELL LINE; DRUG EVALUATION, PRECLINICAL; HUMANS; PYRIMIDINES; VIRUS REPLICATION;

EID: 84891697312     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.02275-13     Document Type: Article

References (58)

1. Buchmeier MJ, Peters CJ, de la Torre JC. 2007. Arenaviridae: the viruses and their replication, p 1792-1827. In Fields BN, Knipe DM, Howley PM (ed), Fields virology, 5th ed, vol 2. Lippincott Williams&Wilkins, Philadelphia, PA.
2. Rojek JM, Kunz S. 2008. Cell entry by human pathogenic arenaviruses. Cell. Microbiol. 10:828-835. http://dx.doi.org/10.1111/j.1462-5822.2007.01113.x.
3. Perez M, Craven RC, de la Torre JC. 2003. The small RING finger protein Z drives arenavirus budding: implications for antiviral strategies. Proc. Natl. Acad. Sci. U. S. A. 100:12978-12983. http://dx.doi.org/10.1073/pnas.2133782100.
4. Lee KJ, Novella IS, Teng MN, Oldstone MB, de La Torre JC. 2000. NP and L proteins of lymphocytic choriomeningitis virus (LCMV) are sufficient for efficient transcription and replication of LCMV genomic RNA analogs. J. Virol. 74:3470-3477. http://dx.doi.org/10.1128/JVI.74.8.3470-3477.2000.
5. Martinez-Sobrido L, Zuniga EI, Rosario D, Garcia-Sastre A, de la Torre JC. 2006. Inhibition of the type I interferon response by the nucleoprotein of the prototypic arenavirus lymphocytic choriomeningitis virus. J. Virol. 80:9192-9199. http://dx.doi.org/10.1128/JVI.00555-06.
6. Martinez-Sobrido L, Giannakas P, Cubitt B, Garcia-Sastre A, de la Torre JC. 2007. Differential inhibition of type I interferon induction by arenavirus nucleoproteins. J. Virol. 81:12696-12703. http://dx.doi.org/10.1128/JVI.00882-07.
7. Rodrigo WW, Ortiz-Riano E, Pythoud C, Kunz S, de la Torre JC, Martinez-Sobrido L. 2012. Arenavirus nucleoproteins prevent activation of nuclear factor kappa B. J. Virol. 86:8185-8197. http://dx.doi.org/10.1128/JVI.07240-11.
8. Carnec X, Baize S, Reynard S, Diancourt L, Caro V, Tordo N, Bouloy M. 2011. Lassa virus nucleoprotein mutants generated by reverse genetics induce a robust type I interferon response in human dendritic cells and macrophages. J. Virol. 85:12093-12097. http://dx.doi.org/10.1128/JVI.00429-11.
9. McCormick JB, Fisher-Hoch SP. 2002. Lassa fever, p 75-110. In Oldstone MB (ed), Arenaviruses I, vol 262. Springer-Verlag, Berlin, Germany.
10. Gunther S, Lenz O. 2004. Lassa virus. Crit. Rev. Clin. Lab. Sci. 41:339-390. http://dx.doi.org/10.1080/10408360490497456.
11. Enria DA, Briggiler AM, Sanchez Z. 2008. Treatment of Argentine hemorrhagic fever. Antiviral Res. 78:132-139. http://dx.doi.org/10.1016/j.antiviral.2007.10.010.
12. Isaacson M. 2001. Viral hemorrhagic fever hazards for travelers in Africa. Clin. Infect. Dis. 33:1707-1712. http://dx.doi.org/10.1086/322620.
13. Holmes GP, McCormick JB, Trock SC, Chase RA, Lewis SM, Mason CA, Hall PA, Brammer LS, Perez-Oronoz GI, McDonnell MK, Paulissen JP, Schonberger LB, Fisher-Hoch SP. 1990. Lassa fever in the United States. Investigation of a case and new guidelines for management. N. Engl. J.Med. 323:1120-1123. http://dx.doi.org/10.1056/NEJM199010183231607.
14. Mets MB, Barton LL, Khan AS, Ksiazek TG. 2000. Lymphocytic choriomeningitis virus: an underdiagnosed cause of congenital chorioretinitis. Am. J. Ophthalmol. 130:209-215. http://dx.doi.org/10.1016/S0002-9394(00)00570-5.
15. Barton LL. 1996. Lymphocytic choriomeningitis virus: a neglected central nervous system pathogen. Clin. Infect. Dis. 22:197.
16. Jahrling PB, Peters CJ. 1992. Lymphocytic choriomeningitis virus: a neglected pathogen of man. Arch. Pathol. Lab. Med. 116:486-488.
17. Palacios G, Druce J, Du L, Tran T, Birch C, Briese T, Conlan S, Quan PL, Hui J, Marshall J, Simons JF, Egholm M, Paddock CD, Shieh WJ, Goldsmith CS, Zaki SR, Catton M, Lipkin WI. 2008. A new arenavirus in a cluster of fatal transplant-associated diseases. N. Engl. J. Med. 358:991-998. http://dx.doi.org/10.1056/NEJMoa073785.
18. Fischer SA, Graham MB, Kuehnert MJ, Kotton CN, Srinivasan A, Marty FM, Comer JA, Guarner J, Paddock CD, DeMeo DL, Shieh WJ, Erickson BR, Bandy U, DeMaria A, Jr, Davis JP, Delmonico FL, Pavlin B, Likos A, Vincent MJ, Sealy TK, Goldsmith CS, Jernigan DB, Rollin PE, Packard MM, Patel M, Rowland C, Helfand RF, Nichol ST, Fishman JA, Ksiazek T, Zaki SR. 2006. Transmission of lymphocytic choriomeningitis virus by organ transplantation. N. Engl. J. Med. 354:2235-2249. http://dx.doi.org/10.1056/NEJMoa053240.
19. Federal Register. 2012. Possession, use, and transfer of select agents and toxins; biennial review. Final rule. Fed. Regist. 77:61083-61115.
20. Rodriguez M, McCormick JB, Weissenbacher MC. 1986. Antiviral effect of ribavirin on Junin virus replication in vitro. Rev. Argent. Microbiol. 18:69-74.
21. Snell N. 1988. Ribavirin therapy for lassa fever. Practitioner 232:432.
22. Kowdley KV. 2005. Hematologic side effects of interferon and ribavirin therapy. J. Clin. Gastroenterol. 39:S3-S8. http://dx.doi.org/10.1097/01.mcg.0000145494.76305.11.
23. McCormick JB, King IJ, Webb PA, Scribner CL, Craven RB, Johnson KM, Elliott LH, Belmont-Williams R. 1986. Lassa fever: effective therapy with ribavirin. N. Engl. J. Med. 314:20-26.
24. Graci JD, Cameron CE. 2006. Mechanisms of action of ribavirin against distinct viruses. Rev. Med. Virol. 16:37-48. http://dx.doi.org/10.1002/rmv.483.
25. Linero FN, Sepulveda CS, Giovannoni F, Castilla V, Garcia CC, Scolaro LA, Damonte EB. 2012. Host cell factors as antiviral targets in arenavirus infection. Viruses 4:1569-1591. http://dx.doi.org/10.3390/v4091569.
26. Sepulveda CS, Garcia CC, Fascio ML, D'Accorso NB, Docampo Palacios ML, Pellon RF, Damonte EB. 2012. Inhibition of Junin virus RNA synthesis by an antiviral acridone derivative. Antiviral Res. 93:16-22. http://dx.doi.org/10.1016/j.antiviral.2011.10.007.
27. Olschlager S, Neyts J, Gunther S. 2011. Depletion of GTP pool is not the predominant mechanism by which ribavirin exerts its antiviral effect on Lassa virus. Antiviral Res. 91:89-93. http://dx.doi.org/10.1016/j.antiviral.2011.05.006.
28. Moreno H, Gallego I, Sevilla N, de la Torre JC, Domingo E, Martin V. 2011. Ribavirin can be mutagenic for arenaviruses. J. Virol. 85:7246-7255. http://dx.doi.org/10.1128/JVI.00614-11.
29. Andrei G, De Clercq E. 1993. Molecular approaches for the treatment of hemorrhagic fever virus infections. Antiviral Res. 22:45-75. http://dx.doi.org/10.1016/0166-3542(93)90085-W.
30. Gowen BB, Wong MH, Larson D, Ye W, Jung KH, Sefing EJ, Skirps-tunas R, Smee DF, Morrey JD, Schneller SW. 2010. Development of a new tacaribe arenavirus infection model and its use to explore antiviral activity of a novel aristeromycin analog. PLoS One 5(9):e12760. http://dx.doi.org/10.1371/journal.pone.0012760.
31. Guillerm G, Guillerm D, Vandenplas-Vitkowski C, Glapski C, De Clercq E. 2003. Inactivation of S-adenosyl-L-homocysteine hydrolase with novel 5'-thioadenosine derivatives: antiviral effects. Bioorg. Med. Chem. Lett. 13:1649-1652. http://dx.doi.org/10.1016/S0960-894X(03)00279-8.
32. Hoffmann HH, Kunz A, Simon VA, Palese P, Shaw ML. 2011. Broadspectrum antiviral that interferes with de novo pyrimidine biosynthesis. Proc. Natl. Acad. Sci. U. S. A. 108:5777-5782. http://dx.doi.org/10.1073/pnas.1101143108.
33. Ortiz-Riano E, Cheng BY, de la Torre JC, Martinez-Sobrido L. 2011. The C-terminal region of lymphocytic choriomeningitis virus nucleoprotein contains distinct and segregable functional domains involved in NP-Z interaction and counteraction of the type I interferon response. J. Virol. 85:13038-13048. http://dx.doi.org/10.1128/JVI.05834-11.
34. Emonet SF, Seregin AV, Yun NE, Poussard AL, Walker AG, de la Torre JC, Paessler S. 2011. Rescue from cloned cDNAs and in vivo characterization of recombinant pathogenic Romero and live-attenuated Candid #1 strains of Junin virus, the causative agent of Argentine hemorrhagic fever disease. J. Virol. 85:1473-1483. http://dx.doi.org/10.1128/JVI.02102-10.
35. Flatz L, Bergthaler A, de la Torre JC, Pinschewer DD. 2006. Recovery of an arenavirus entirely from RNA polymerase I/II-driven cDNA. Proc. Natl. Acad. Sci. U. S. A. 103:4663-4668. http://dx.doi.org/10.1073/pnas.0600652103.
36. Ortiz-Riano E, Cheng BY, Carlos de la Torre J, Martinez-Sobrido L. 2013. Arenavirus reverse genetics for vaccine development. J. Gen. Virol. 94:1175-1188. http://dx.doi.org/10.1099/vir.0.051102-0.
37. Rodrigo WW, de la Torre JC, Martinez-Sobrido L. 2011. Use of single-cycle infectious lymphocytic choriomeningitis virus to study hemorrhagic fever arenaviruses. J. Virol. 85:1684-1695. http://dx.doi.org/10.1128/JVI.02229-10.
38. Emonet SE, Urata S, de la Torre JC. 2011. Arenavirus reverse genetics: new approaches for the investigation of arenavirus biology and development of antiviral strategies. Virology 411:416-425. http://dx.doi.org/10.1016/j.virol.2011.01.013.
39. Berridge MV, Tan AS. 1993. Characterization of the cellular reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT): subcellular localization, substrate dependence, and involvement of mitochondrial electron transport in MTT reduction. Arch. Biochem. Biophys. 303:474-482.
40. Urata S, Ngo N, de la Torre JC. 2012. The PI3K/Akt pathway contributes to arenavirus budding. J. Virol. 86:4578-4585. http://dx.doi.org/10.1128/JVI.06604-11.
41. Munger J, Bennett BD, Parikh A, Feng XJ, McArdle J, Rabitz HA, Shenk T, Rabinowitz JD. 2008. Systems-level metabolic flux profiling identifies fatty acid synthesis as a target for antiviral therapy. Nat. Biotechnol. 26:1179-1186. http://dx.doi.org/10.1038/nbt.1500.
42. Melamud E, Vastag L, Rabinowitz JD. 2010. Metabolomic analysis and visualization engine for LC-MS data. Anal. Chem. 82:9818-9826. http://dx.doi.org/10.1021/ac10211166.
43. Baldwin J, Farajallah AM, Malmquist NA, Rathod PK, Phillips MA. 2002. Malarial dihydroorotate dehydrogenase. Substrate and inhibitor specificity. J. Biol. Chem. 277:41827-41834. http://dx.doi.org/10.1074/jbc.M206854200.
44. Baldwin J, Michnoff CH, Malmquist NA, White J, Roth MG, Rathod PK, Phillips MA. 2005. High-throughput screening for potent and selective inhibitors of Plasmodium falciparum dihydroorotate dehydrogenase. J. Biol. Chem. 280:21847-21853. http://dx.doi.org/10.1074/jbc.M501100200.
45. Kulkarni OP, Sayyed SG, Kantner C, Ryu M, Schnurr M, Sardy M, Leban J, Jankowsky R, Ammendola A, Doblhofer R, Anders HJ. 2010. 4SC-101, a novel small molecule dihydroorotate dehydrogenase inhibitor, suppresses systemic lupus erythematosus in MRL-(Fas)lpr mice. Am. J. Pathol. 176:2840-2847. http://dx.doi.org/10.2353/ajpath.2010.091227.
46. Markland W, McQuaid TJ, Jain J, Kwong AD. 2000. Broad-spectrum antiviral activity of the IMP dehydrogenase inhibitor VX-497: a comparison with ribavirin and demonstration of antiviral additivity with alpha interferon. Antimicrob. Agents Chemother. 44:859-866. http://dx.doi.org/10.1128/AAC.44.4.859-866.2000.
47. Pinschewer DD, Perez M, de la Torre JC. 2003. Role of the virus nucleoprotein in the regulation of lymphocytic choriomeningitis virus transcription and RNA replication. J. Virol. 77:3882-3887. http://dx.doi.org/10.1128/JVI.77.6.3882-3887.2003.
48. Emonet SF, Garidou L, McGavern DB, de la Torre JC. 2009. Generation of recombinant lymphocytic choriomeningitis viruses with trisegmented genomes stably expressing two additional genes of interest. Proc. Natl. Acad. Sci. U. S. A. 106:3473-3478. http://dx.doi.org/10.1073/pnas.0900088106.
49. Evans DR, Guy HI. 2004. Mammalian pyrimidine biosynthesis: fresh insights into an ancient pathway. J. Biol. Chem. 279:33035-33038. http://dx.doi.org/10.1074/jbc.R400007200.
50. Knecht W, Loffler M. 1998. Species-related inhibition of human and rat dihydroorotate dehydrogenase by immunosuppressive isoxazol and cinchoninic acid derivatives. Biochem. Pharmacol. 56:1259-1264.
51. Leyssen P, Balzarini J, De Clercq E, Neyts J. 2005. The predominant mechanism by which ribavirin exerts its antiviral activity in vitro against flaviviruses and paramyxoviruses is mediated by inhibition of IMP dehydrogenase. J. Virol. 79:1943-1947. http://dx.doi.org/10.1128/JVI.79.3.1943-1947.2005.
52. Moreno H, Grande-Perez A, Domingo E, Martin V. 2012. Arenaviruses and lethal mutagenesis: prospects for new ribavirin-based interventions. Viruses 4:2786-2805. http://dx.doi.org/10.3390/v4112786.
53. Lucas-Hourani M, Dauzonne D, Jorda P, Cousin G, Lupan A, Helynck O, Caignard G, Janvier G, Andre-Leroux G, Khiar S, Escriou N, Despres P, Jacob Y, Munier-Lehmann H, Tangy F, Vidalain PO. 2013. Inhibition of pyrimidine biosynthesis pathway suppresses viral growth through innate immunity. PLoS Pathog. 9(10):e1003678. http://dx.doi.org/10.1371/journal.ppat.1003678.
54. Traut TW, Jones ME. 1996. Uracil metabolism. UMP synthesis from orotic acid or uridine and conversion of uracil to beta-alanine: enzymes and cDNAs. Prog. Nucleic Acid Res. Mol. Biol. 53:1-78.
55. Volberding PA, Deeks SG. 1998. Antiretroviral therapy for HIV infection: promises and problems. JAMA 279:1343-1344. http://dx.doi.org/10.1001/jama.279.17.1343.
56. Hotho DM, de Bruijne J, Spaan M, Treitel MA, Boonstra A, de Knegt RJ, Janssen HL, Reesink HW. 2013. Sustained virologic response after therapy with the HCV protease inhibitor narlaprevir in combination with peginterferon and ribavirin is durable through long-term follow-up. J. Viral Hepat. 20:e78-e81. http://dx.doi.org/10.1111/jvh.12012.
57. Haasbach E, Hartmayer C, Planz O. 2013. Combination of MEK inhibitors and oseltamivir leads to synergistic antiviral effects after influenza A virus infection in vitro. Antiviral Res. 98:319-324. http://dx.doi.org/10.1016/j.antiviral.2013.03.006.
58. Oh J, O'Connor PW. 2013. An update of teriflunomide for treatment of multiple sclerosis. Ther. Clin. Risk Manag. 9:177-190. http://dx.doi.org/10.2147/TCRM.S30947.